Putilina M V, Mutovina Z Yu, Kurushina O V, Khalilova D M, Saverskaya E N, Stepanova S B, Khoreva M A, Starikov A S
Pirogov Russian National Research Medical University, Moscow, Russia.
City Clinical Hospital No. 52, Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(1):84-90. doi: 10.17116/jnevro202212201184.
To study the prevalence of clinical manifestations of postcoid syndrome in patients at an outpatient neurological appointment, to evaluate the effectiveness of therapy regimens using Cortexin at doses of 10 mg and 20 mg IM for 10 days.
674 neurologists from all regions of the Russian Federation, Azerbaijan, Kyrgyzstan and Kazakhstan took part in the study. A total of 979 COVID-19 patients were recruited. The average age is 54.6±0.45 years. The duration of the transferred SARS-CoV-2 days and from 1 month or more 12. 3 visits were carried out: 1 on the day of treatment (assessment of complaints, analysis of scale indicators, prescription of the drug Cortexin in doses of 10-20 mg/m for 10 days). 2 (telephone survey) visit for 10-14 days, 3 visit - for 30 days at the reception. The condition was assessed using the Asthenia Assessment Scale (MFI-20), the Brief Mental Status Assessment Scale (MMSE questionnaire), the Schulte test, and the Subjective Treatment Quality Assessment Scale.
The daily proportion of patients with complaints after a previous coronavirus infection was 30% in the total structure of neurological admission. The most common complaints: fatigue, general weakness, decreased memory and concentration, dizziness, sleep disturbance, irritability, aggression, shortness of breath, pain syndromes, excessive sweating, anosmia, hyposmia, perverted taste of paresthesia, hair loss, blurred vision, unstable blood pressure, tachycardia, allergic reactions, menstrual irregularities, erectile dysfunction, apathy, panic attacks, suicidal thoughts, depression, refusal to eat meat.
There was no significant correlation of clinical symptoms with the severity of COVID-19, the percentage of lung tissue damage, and different periods of postcovid syndrome. The clinical efficacy of the drug Cortexin in dosages of 10 and 20 mg for the correction of cognitive and asthenic disorders has been proven. Revealed anti-anxiety, antidepressant and anxiolytic activity of Cortexin is more pronounced when using a dosage of 20 mg.
研究在门诊神经科就诊患者中新冠后综合征的临床表现患病率，评估使用剂量为10毫克和20毫克的脑蛋白水解物肌肉注射10天的治疗方案的有效性。
来自俄罗斯联邦所有地区、阿塞拜疆、吉尔吉斯斯坦和哈萨克斯坦的674名神经科医生参与了该研究。共招募了979名新冠患者。平均年龄为54.6±0.45岁。感染新冠病毒的天数为1个月或更长时间，进行了3次就诊：第1次在治疗当天（评估症状、分析量表指标、开具剂量为10 - 20毫克/米的脑蛋白水解物药物，为期10天）。第2次（电话调查）在10 - 14天进行，第3次就诊在门诊30天时进行。使用疲劳评估量表（MFI - 20）、简易精神状态评估量表（MMSE问卷）、舒尔特测试和主观治疗质量评估量表对病情进行评估。
在神经科门诊患者的总体结构中，既往新冠病毒感染后有症状患者的每日比例为30%。最常见的症状：疲劳、全身无力、记忆力和注意力下降、头晕、睡眠障碍、易怒、攻击性、呼吸急促、疼痛综合征、多汗、嗅觉减退、味觉异常、脱发、视力模糊、血压不稳定、心动过速、过敏反应、月经不调、勃起功能障碍、冷漠、惊恐发作、自杀念头、抑郁、拒食肉类。
临床症状与新冠的严重程度、肺组织损伤百分比以及新冠后综合征的不同时期之间没有显著相关性。已证实剂量为10毫克和20毫克的脑蛋白水解物药物在纠正认知和虚弱障碍方面具有临床疗效。当使用20毫克剂量时，脑蛋白水解物的抗焦虑、抗抑郁和抗焦虑活性更为明显。
